Nano Pharmaceuticals
Market Cap
₹86 ₹86.00 Cr.
P/E
7.51
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
-
Div Yield (%)
Div Yield (%)
1.17
Individual < 2 lac
Individual < 2 lac
12.42 %
Institutions
Institutions
-
Market cap
Market cap
86.00 Cr
No. of Shareholders
No. of Shareholders
1,483
OPM (%)
OPM (%)
-
PE
PE
7.51
Prom Holding
Prom Holding
70.65 %
ROCE (%)
ROCE (%)
19.06
ROE (%)
ROE (%)
14.17
Sales
Sales
45.49 Cr
  • Amwill Health Care
  • Vaishali Pharma
  • Trident Lifeline
Last updated on
      Price Range

      See where the stock is trading versus its 52-week high and low.

      Low
      29
      52W Range
      High
      63
      Timeline

      Key company specific updates.

      Custom financial statement

      Edit rows

      Forensics

      6 Yes

      Positive for this company

      3 Neutral

      Neutral for this company

      5 No

      Negative for this company

      3 No Data

      Insufficient data to analyse

      Revenue mix

      Product Wise Break-Up

      Location Wise Break-Up

      Peer Comparison

      Corporate Actions

      Consolidated
      DATE
      DETAILS
      Show More
      Show Less
      Show More
      Show Less

      FAQs on Amwill Health Care Ltd. Business

      Amwill Health Care is a derma-cosmetic development company, associated with contract manufacturers, distributor and third-party product development agencies, which has enabled it in developing capabilities, in manufacturing, packaging and distribution.

      Amwill Health Care major competitors are Vaishali Pharma, Trident Lifeline.
      Market Cap of Amwill Health Care is ₹87 Crs.
      While the median market cap of its peers are ₹230 Crs.

      Amwill Health Care seems to be financially stable compared to its competitors.
      The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

      Company Filing

      2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
      Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
      Earnings Release
      Investor Presentation
      Conference Call
      Conference Call SummaryCon Call Summary

      Discussions & Analysis

      Ideas Dashboard
      Results
      Timeline
      Watchlist
      Portfolio
      Alerts
      Stock Screener
      Market
      Raw Material